Dr. Sri P Srivastava: The management team is led by Sri P Srivastava, PhD, who has more than 20 years of experience in drug development including discovery, preclinical toxicology & clinical operations within the US industry. Prior to founding ClinTech Research, Dr. Srivastava has held positions with progressive management responsibilities at large to mid-size multinational pharmaceutical companies like Parke-Davis, Pfizer, Purdue Pharma, and Organon Pharmaceuticals. Before joining the pharmaceutical industry, Dr. Srivastava worked as a research scientist at Howard Hughes Medical Institute/ University of Michigan, Ann Arbor. He has published more than 20 publications in peer reviewed journals; and has been invited as a speaker at various national and international symposiums. Dr. Srivastava has earned his Doctor of Philosophy (PhD) in Biochemistry and his Master of Science (MS) from Banaras Hindu University in India.

Dr. Tage Honore: Dr. Tage Honore is the senior advisor for ClinTech Research, and is the founder, president and CEO of Aestus Therapeutics, Inc, a biotechnology company. Dr. Honore has a distinguished career in pharmaceutical research, championing development of ideas to progress into early clinical studies. Previously, Vice President at Novartis, Novo Nordisk and Purdue Pharma, he has contributed to more than 35 new molecular entities entering clinical development. For ten years he was opinion leader in the Excitatory Amino Acid Receptor field and contributed considerably to the progress and understanding of this important neuronal pathway. His passion for and skill in interacting with people and with different cultures has enabled development of new organizational models to obtain record pipeline productivity in several companies. Dr. Honore earned his Doctor of Philosophy in Medicinal Chemistry and his Doctor of Science degree in Neurobiology from the Royal Danish School of Pharmacy in Denmark. He continued his training in business at both the Harvard Business School and the European Management Centre.

Carl G Osborne: Carl G Osborne, D.V.M is the advisor and senior consultant for ClinTech Research, and is the founder and a principal officer of SciLucent, Inc. Mr. Osborne is an internationally recognized expert in drug development, business development, strategic planning and operational process improvement. He has undertaken or overseen numerous due diligence exercises for drug, biologics, and medical devices; helped define business, scientific, and regulatory strategies for development-stage companies; assisted clients in the planning and execution of numerous product development plans, prepared INDs, IDEs, NDAs, BLAs, CTAs, and MAAs; and worked to help companies develop better operational systems (e.g., Project/Program Management, Outsource Management, Compliance Management, etc.). He is a former FDA toxicologist and compliance officer with extensive experience in international regulatory affairs, and quality systems (cGMP, GLP, GCP, QSR,) design, implementation, management, and remediation. Carl’s expertise includes monoclonal antibodies, oncology drugs, neurology drugs, antibiotics, cardiovascular drugs, pulmonary drugs, and gastrointestinal drugs.